CorPath GRX is a second generation robotic-assisted system built on the foundation of the CorPath 200’s clinical success with over 8,000 cases across more than 65 programs worldwide.
When using the CorPath System, studies have shown:*
The CORA-PCI Trial demonstrated 99.1% clinical success in complex cases along with comparable procedure times to manual PCI.1
A single center study published in Circulation: Cardiovascular Interventions demonstrated a 20% reduction in radiation dose to the patient compared to manual PCI.2
A recent study demonstrated that accurate measurement of coronary anatomy, using CorPath, reduced the use of unnecessary additional stents by 8.3%.3
The PRECISE trial demonstrated a 95% reduction in radiation exposure to the primary operator.4
1. Mahmud E, et al. Demonstration of the Safety and Feasibility of Robotically Assisted Percutaneous Coronary Intervention in Complex Coronary Lesions: Results of the Complex Robotically Assisted Percutaneous Coronary Intervention (CORA-PCI) Trial. Presented at SCAI 2016; Orlando, FL.
2. Patel T, et al. Comparison of Robotic Percutaneous Coronary Intervention With Traditional Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2020; 13:e008888. DOI: 10.1161/CIRCINTERVENTIONS.119.008888.
3. Campbell PT, et al. The Impact of Precise Robotic Lesion Length Measurement on Stent Length Selection: Ramification for stent savings. Cardiovasc Revasc Med. 2015;piii:S1553-8389.
4. Weisz G, et al. Safety and Feasibility of Robotic Percutaneous Coronary Intervention: PRECISE Study. J American College of Cardiol, 2013, Vol 61, No. 15: 1596-1600.
* Includes studies conducted using CorPath 200
** Compared to the CorPath 200 System
